MONTREAL, March 27, 2013 /CNW Telbec/ - "It is with great disappointment
that Sanofi Canada has learned that the Institut national d'excellence en santé et en services sociaux (INESSS) has not approved the public listing of JEVTANA®
(cabazitaxel)," said Jon Fairest, President and CEO of Sanofi Canada.
"This decision means that those men living with prostate cancer in
Quebec and dependent on the public system will not have access to
public reimbursement for JEVTANA®."
The provinces of Alberta, Saskatchewan, Manitoba and Ontario have
already approved and recognized the value of JEVTANA® for patients
living in these provinces.
Sanofi Canada's ambition is to bring value, health and hope to Canadians
through innovative healthcare solutions. Sanofi Canada stands behind
the principle of access to the right medicine for the right patient at
the right time, in strict accordance with advice and oversight from the
appropriate healthcare practitioner.
"It is an exciting time in the area of prostate cancer research with
several new treatment options recently approved by Health Canada.
Scientific research and clinical evidence suggests that there are
subgroups of patients who respond differently to these different
treatment options, therefore, the ability to individualize treatment is
what is necessary to provide best outcomes for patients ," added Mr.
Fairest. "Not having Cabazitaxel available to physicians and patients
as a treatment option is extremely disappointing. We can just begin to
imagine how frustrating this will be for patients and their families.
New drugs with recognized therapeutic value need to be accessible to
patients and clinicians in order to accomplish the objective and offer
the best chance of extending survival."
Regardless of the recent decision by INESSS to not approve JEVTANA®,
Sanofi hopes to have the opportunity to work with INESSS in the very
near future to help make this unique treatment option available to
prostate cancer patients who can benefit from it.
JEVTANA® is a second line treatment of castration resistant (hormone
refractory) metastatic prostate cancer (mHRPC) in combination with
prednisone in patients who have received prior treatment with a
docetaxel containing regimen.
Jevtana® is a registered trademark of Sanofi.
Sanofi, a global and diversified healthcare leader, discovers, develops
and distributes therapeutic solutions focused on patients' needs.
Sanofi has core strengths in the field of healthcare with seven growth
platforms: diabetes solutions, human vaccines, innovative drugs,
consumer healthcare, emerging markets, animal health and the new
Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York
Sanofi companies in Canada include sanofi-aventis Canada Inc.
(pharmaceuticals), Sanofi Pasteur (vaccines), Sanofi Consumer Health
(health and beauty), Genzyme (rare diseases) and Merial (animal
health). Together they employ more than 1,700 people, mainly in the
greater Montreal and Toronto areas. In 2011 Sanofi companies invested
$151.7 million in R&D in Canada, creating jobs, business and
opportunity throughout the country. For additional information, please
visit http://www.sanofi.ca .
SOURCE: SANOFI CANADA
For further information:
Communications Consultant, Sanofi Canada